WuXi STA will set up a new R&D Center

| By | API, China, R&D, WuXi AppTec

STA Pharmaceutical Co., Ltd., a subsidiary of WuXi AppTec (WuXi STA), signed an investment agreement with the government of Shanghai (China) Jinshan District to build a new R&D center.

The new facility will further strengthen WuXi STA’s global leading pharmaceutical development and manufacturing platform, enabling drug developers to accelerate their projects from preclinical to commercial stage.

Over the years, WuXi STA has established an industry leading process development platform with over 1,000 scientists and five sites located in China and the United States. WuXi STA’s Jinshan site currently focuses on manufacturing innovative Active Pharmaceutical Ingredients (APIs) and advanced intermediates from kilo to metric ton scale. The site has been approved by multiple international regulatory agencies including US FDA.

The new R&D center is located next to the existing Jinshan drug substance manufacturing site. It will add more than 30,000 square meters of laboratory space and 500 scientists. Upon completion, the new Jinshan campus will be able to offer integrated one-site solution for partners to push forward innovative APIs and advanced intermediates through preclinical and clinical development to global commercial launch. The new campus will also offer the access to many industry-leading technology platforms such as flow chemistry, biocatalysis, and high potency, from laboratory to commercial scale.

SOURCE: wuxi apptec
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.